<DOC>
	<DOCNO>NCT01162980</DOCNO>
	<brief_summary>ACE inhibitor study extensively treatment heart failure show beneficial stage . Studies use angiotensin receptor blocker ( ARBs ) chronic heart failure show equivalent result . Many patient ARB variety reason . Some may cough symptom heart failure due medication side effect . According guideline , angiotensin convert enzyme inhibitor ( ACEi ) still first-line therapy treatment heart failure . As ACEi extensively study show improvement morbidity mortality patient treatment unless absolutely contraindicate .</brief_summary>
	<brief_title>The Angiotensin Converting Enzyme ( ACE ) Inhibitor SwitchBack Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>heart failure patient indication ACEi currently ARBs absolute contraindication ACEi patient ejection fraction &lt; = 35 % verify last 12 month echo , angio , nuc med NYHA class I IV followed heart failure clinic three month betablockers , unless contraindicate stable current med 3 month ( except dose diuretic ) able give inform consent document angioedema/anaphylaxis prior ACEi use document worsen renal failure , hyperkalemia , cough gastrointestinal symptom definitely believe due ACEi potassium &gt; 5.0 mmol/L</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>ACE inhibitor</keyword>
	<keyword>ARBs</keyword>
</DOC>